Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Other Names for this Disease
  • Pancreatic VIPoma
  • Vasoactive intestinal peptide (VIP) tumor
  • Vasoactive intestinal peptide-producing tumor
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Overview



What is VIPoma?

How might VIPoma be treated?


What is VIPoma?

VIPoma is a rare cancer that develops within the pancreas. This tumor causes pancreatic cells to produce high levels of a hormone called vasoactive intestinal peptide (VIP). The signs and symptoms of a VIPoma include abdominal pain, flushing or redness of the face, nausea, watery diarrhea, weight loss, dehydration, and low blood potassium (hypokalemia). VIPomas are usually diagnosed in adults around age 50. The cause of VIPoma is unknown. Treatment may include intravenous (IV) fluids to correct dehydration, medications such as octreotide to help control diarrhea, and surgery to remove the tumor.[1]
Last updated: 3/8/2010

How might VIPoma be treated?

Treatment for VIPoma may include intravenous (IV) fluids to correct dehydration, medications such as octreotide to help control diarrhea, and surgery to remove the tumor.[1] If the tumor has spread (metastasized) to the liver or other tissues, treatment may involve chemotherapyradiofrequency ablation, or hepatic artery embolization.[2][3][4][5]
Last updated: 3/8/2010

References
  1. Stitham SO. VIPoma. MedlinePlus Web site. September 4, 2008; http://www.nlm.nih.gov/medlineplus/ency/article/000228.htm. Accessed 3/8/2010.
  2. Song S, Shi R, Li B, Liu Y. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas. 2009 Oct;38(7):811-4.  http://www.ncbi.nlm.nih.gov/pubmed/19657309 .
  3. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL, Yeo CJ. Pancreatic VIPomas: subject review and one institutional experience. J Gastrointest Surg. 2008 Feb;12(2):382-93. http://www.ncbi.nlm.nih.gov/pubmed/17510774 .
  4. Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology. 2006;6(1-2):155-159 http://www.ncbi.nlm.nih.gov/pubmed/16354964.
  5. Case CC, Wirfel K, Vassilopoulou-Sellin R. Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report. Med Oncol. 2002;19(3):181-187 http://www.ncbi.nlm.nih.gov/pubmed/12482130.